Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) EBITDA (2022 - 2025)

Bioregenx (BRGX) has 4 years of EBITDA data on record, last reported at -$73343.0 in Q3 2025.

  • For Q3 2025, EBITDA rose 81.55% year-over-year to -$73343.0; the TTM value through Sep 2025 reached -$18.9 million, down 147.08%, while the annual FY2024 figure was -$23.1 million, 543.65% down from the prior year.
  • EBITDA reached -$73343.0 in Q3 2025 per BRGX's latest filing, up from -$185542.0 in the prior quarter.
  • Across five years, EBITDA topped out at $18209.0 in Q3 2022 and bottomed at -$18.4 million in Q4 2024.
  • Average EBITDA over 4 years is -$2.0 million, with a median of -$268913.0 recorded in 2025.
  • Peak YoY movement for EBITDA: crashed 54184.37% in 2023, then soared 91.47% in 2025.
  • A 4-year view of EBITDA shows it stood at -$5535.0 in 2022, then plummeted by 54184.37% to -$3.0 million in 2023, then crashed by 512.27% to -$18.4 million in 2024, then skyrocketed by 99.6% to -$73343.0 in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$73343.0 in Q3 2025, -$185542.0 in Q2 2025, and -$268913.0 in Q1 2025.